drug interaction(s) of ACE inhibitors with angiotensin II receptor antagonists

From Aaushi
Jump to navigation Jump to search

Drug interactions

Management

More general terms

References

  1. 1.0 1.1 Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007 Oct 8;167(18):1930-6. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17923591
  2. 2.0 2.1 2.2 Yusuf S et al for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18378520
  3. 3.0 3.1 Bangalore S et al Antihypertensive drugs and risk of cancer: network meta- analyses and trial sequential analyses of 324 168 participants from randomised trials The Lancet Oncology, Early Online Publication, 30 November 2010 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21123111 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70260-6/fulltext
  4. Makani H et al Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ 2013;346:f360 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23358488 <Internet> http://www.bmj.com/content/346/bmj.f360
  5. 5.0 5.1 Fernandez Juarez G et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. Am J Kidney Dis 2013 Feb; 61:211 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22939518
  6. 6.0 6.1 Fried LF et al Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. N Engl J Med. 2013 Nov 9. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/24206457
    de Zeeuw D. The End of Dual Therapy with Renin-Angiotensin-Aldosterone System Blockade? N Engl J Med. 2013 Nov 9. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/24206456
  7. 7.0 7.1 Prescriber's Letter 10(5):26 2003